Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/05/21
Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock?Zacks Investment Research • 12/14/20
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene TherapyBusiness Wire • 12/07/20
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial ResultsBusiness Wire • 11/04/20
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and WebcastBusiness Wire • 10/28/20
Will Sangamo Therapeutics (SGMO) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/28/20
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy TreatmentBusiness Wire • 10/07/20
Sangamo: $665M In Cash Ready To Be Deployed Across A Pipeline Of 18 Therapeutics And 2 New 2020 Partnerships, 29% UpsideSeeking Alpha • 10/06/20
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare ConferenceBusiness Wire • 08/10/20
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial ResultsBusiness Wire • 08/05/20
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental DisordersBusiness Wire • 07/30/20
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and WebcastBusiness Wire • 07/29/20
Sangamo Therapeutics (SGMO) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 07/29/20